Intelligent Bio Solutions Inc. - Common Stock (INBS)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Mar 30, 2026Investment Snapshot
- P/B of 0.47 — trading below book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -94.2%
Intelligent Bio Solutions Inc. - Common Stock (INBS) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $5 million . Key value metrics: P/B ratio 0.47, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Intelligent Bio Solutions Inc. - Common Stock — Fundamental Analysis Summary
On financial health, INBS shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -94.2% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.15.
StockPik's composite Value Score for INBS is 75/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
INBS reports a solid gross margin of 42.2% (sector average: 33.5%) and a negative operating margin of -286.2%.
INBS shows revenue declining at 2% year-over-year, with earnings declining at 4%.